Which is better value, the AstraZeneca or GSK share price?

The GSK share price has fallen behind in the past few years. But do Q3 earnings mean we should expect a reversal of fortune soon?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Image source: GSK plc

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Over the past five years, AstraZeneca has soared while the GSK (LSE: GSK) share price has gone nowhere.

That period does cover the Covid pandemic, when AstraZeneca became one of the top vaccine stars. But is GSK now the better buy? I think it is, and I’ll tell you why.

Third quarter

GSK posted Q3 results on 1 November.

The firm is big in vaccines, even it it didn’t catch the Covid headlines. Vaccine sales in the quarter rose 33%.

GSK has launched the world’s first vaccine, Arexvy, for the respiratory virus RSV. And that gave it a nice boost.

Overall, total Q3 sales rose by 10%, and by 16% excluding Covid products. Adjusted earnings per share for the year to date gained 11%.

The firm lifted its full-year adjusted EPS growth outlook into the 17%-20% range, from 14%-17%. And it expects to pay a 56.5p full-year dividend.

Long-term outlook

So, how did the GSK share price react? With a 1.7% drop by midday. It seems you just can’t please the market these days.

And as if to rub it in, AstraZeneca shares are up a fraction at the time of writing.

GSK CEO Emma Walmsley says: “GSK’s longer-term outlook also continues to strengthen, with progress in our vaccines pipeline, the development of our ultra long-acting HIV portfolio and significant new prospects in respiratory“.

So what do the valuations of the FTSE 100’s big two pharma stocks look like?

Twice the value?

AstraZeneca is currently valued at a price-to-earnings (P/E) ratio of way more than twice that of GSK shares.

Broker forecasts put AstraZeneca on a multiple of almost 28, against GSK’s measly 10.

With the share price disjoint, the dividend yields don’t line up. AstraZeneca is on a modest 2.3%, while GSK’s just-announced figure would yield 4%.

To counter that, AstraZeneca’s earnings growth forecasts are ahead of GSK’s.

My choice

The City expects AstraZeneca earnings to grow by 54% between 2023 and 2025. Over at GSK, the mooted growth is just 11%.

Still, even if they’re right, that would still leave AstraZeneca at around twice the valuation by 2025, on a P/E of 18.

As it happens, I do think that could make the stock good value now. It’s certainly not outrageous for a growth stock.

But by 2025, we’d see the P/E at GSK drop to around nine, if earnings forecasts are accurate. And that just seems crazy cheap to me, for one of the world’s top pharma firms.

Too good to be true?

There is one key risk with GSK right now, which I’m sure affects its stock valuation.

It faces a number of lawsuits in the US over claims made against its heartburn medication Zantac. GSK refutes the claims, has settled a few lawsuits already, and others have been thrown out.

But the costs of fighting litigation could keep investors away from the GSK shares for a while yet.

Still, even with that, GSK is on my list of long-term buy candidates.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca Plc and GSK. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing For Beginners

How to try and build a £250k Stocks and Shares ISA from scratch, starting in 2024

With a regular savings plan and a smart investment strategy, it’s possible to build wealth within a Stocks and Shares…

Read more »

Investing Articles

I’m considering 3 top UK dividend stocks for my portfolio this July

Mark David Hartley is looking at adding a few dividend stocks to his portfolio this month. Will these three shares…

Read more »

Investing Articles

3 FTSE 100 shares I’d buy to create lasting passive income

Dividend stocks are a great way to build an additional income. Our writer details three FTSE 100 picks she’d love…

Read more »

Investing Articles

After falling 9% in 6 weeks, is this FTSE 100 stock now in bargain territory?

The BAE Systems share price hit a 52-week high on 3 June. Six weeks later, it’s down nearly 10%. Is…

Read more »

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

I love the look of Entain shares, potentially 47% undervalued

Many FTSE 100 companies have been on a tear in 2024, but with Entain shares down nearly 50%, I think…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

Could Aviva shares reach £5.84 in the next 12 months?

Some analysts think Aviva shares could soar nearly 19% in the next year. This Fool takes a closer look to…

Read more »

Investing Articles

I’m looking at a once-in-a-decade chance to buy dirt-cheap FTSE dividend shares

Harvey Jones says FTSE 100 dividend shares have been showing signs of life lately but they're still cheap and there's…

Read more »

Arrow symbol glowing amid black arrow symbols on black background.
Investing Articles

If I’d put £10k in BAE Systems shares 10 years ago, here’s what I’d have now

BAE Systems shares have been on fire over the last decade. But just how much would a £10k investment back…

Read more »